As gabapentin climbs the ranks to become one of the most prescribed medications in the U.S., questions about its safety and scope of use are also rising. This episode explores recent trends in gabapentin use, highlights key patient safety concerns, and examines pharmacist-led opportunities to reduce risks through education and medication review. You will walk away with timely insights to help navigate the growing complexities and responsibilities associated with gabapentin use.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

GUEST
Nakia Duncan, PharmD BCGP, BCPS
Associate Professor/ Pain& Palliative Care Clinical Pharmacist
Texas Tech Health Science Center - School of Pharmacy

GET CE FOR THIS LISTENING!
The GameChangers Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. 

PRACTICE RESOURCE
Purchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.

 
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:

• If you are already enrolled in this course, click here to redeem your credit. 
• To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here. 

 CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Summarize recent national prescribing trends and safety concerns associated with gabapentin use.
2. Identify pharmacist-led strategies to support safe use, patient education, and medication review involving
gabapentin.

Rachel Maynard and Nakia Duncan have no relevant financial relationships with ineligible companies to disclose.

0.05 CEU/0.5 Hr
UAN: 0107-0000-26-053-H01-P
Initial release date: 2/23/2026
Expiration date: 2/23/2027
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram